46333XAF5

Ironwood Pharmaceuticals, Inc.

Could not find a ticker for this position, may be a filing error

A Boston-based biotechnology company that develops and sells medicines for digestive and rare diseases, best known for Linzess, a prescription treatment for chronic constipation and irritable bowel syndrome. It began in 1998 as Microbia, founded by postdocs from a Whitehead Institute lab, and renamed itself Ironwood in 2008 after the long-lived desert tree that shelters other plants — a nod to endurance. Its flagship drug linaclotide was discovered by those same early researchers.

CONVERTIBLEUnderlying: IRWDCUSIP: 46333XAF5HealthcareUS1 derivative reporter

0.75% Convertible Senior Notes due 2024

Ownership Activity Financials Filings

46333XAF5

46333XAF5

Results of Operations and Financial Condition

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

Other Events

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

Results of Operations and Financial Condition

Other Events

Results of Operations and Financial Condition

Results of Operations and Financial Condition